Thursday, September 23, 2010

Dabigatran a slam dunk in FDA advisory panel

From Medscape:

Barring any unforeseen damning revelations about the drug, the FDA's approval of the oral thrombin inhibitor dabigatran (Pradaxa, Boehringer Ingelheim) for stroke prevention in atrial fibrillation (AF) is all but certain.

Does that mean warfarin genotyping will be ready for prime time no sooner than it becomes obsolete? I doubt it. Dabigatran will only be approved for stroke prevention in atrial fibrillation. It may be years before it's validated for treatment of VTE.

No comments: